Durvalumab outcomes for patients with PD-L1 positive and negative stage III unresectable non-small cell lung cancer treated at veterans health administration facilities

被引：0

作者：

Burton, Elizabeth M.

Moore, Amanda

Nooruddin, Zohra

Cotarla, Ion

Simmons, Daniel

Davis, Laura

Reveles, Kelly R.

Datta, Paromita

Souza, Gabriel Roman

Irabor, Omoruyi Credit

Franklin, Kathleen

Jones, Xavier

Frei, Christopher R.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA

[3] Univ Texas Hlth San Antonio, San Antonio, TX USA

[4] AstraZeneca, Gaithersburg, MD USA

[5] Univ Texas Austin, San Antonio, TX USA

[6] South Texas Vet Hlth Care Syst, San Antonio, TX USA

[7] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e18793

引用

页数：1

共 50 条

[21] Prognostic Significance of PD-L1 in Stage II/III Non-Small Cell Lung Cancer
Karaca, M.
Tura, D.
Ozet, A.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S628 - S628
[22] PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer
Smit, Jasper
Borm, Frank J.
Niemeijer, Anna-Larissa N.
Huisman, Marc C.
Hoekstra, Otto S.
Boellaard, Ronald
Oprea-Lager, Daniela E.
Vugts, Danielle J.
van Dongen, Guus A. M. S.
de Wit-van der Veen, Berlinda J.
Thunnissen, Erik
Smit, Egbert F.
de Langen, Adrianus J.
JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (05) : 686 - 693
[23] Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice
Furuhashi, K.
Hataji, O.
Nakamura, Y.
Suzuki, Y.
Sakaguchi, T.
Ito, K.
Fujiwara, K.
Nishii, Y.
Taguchi, O.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1104 - S1104
[24] CLINICAL INVESTIGATION Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab
Sankar, Kamya
Strohbehn, Garth W.
Zhao, Lili
Daniel, Victoria
Elliott, David
Ramnath, Nithya
Green, Michael D.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (04): : 752 - 758
[25] Clinical Outcomes and Lack of Health Equity in Minority Patients with Unresectable Non-small Cell Lung Cancer (NSCLC) Treated with Durvalumab
Fares, A.
Theik, N.
Dumais, K.
Walker, D.
Rodriguez, M.
Dickson, F.
Swaby, G.
Alvarez, A. M.
Raez, L. E.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S741 - S741
[26] Real-Life Study of Patients with Unresectable Stage III Non-Small Cell Lung Cancer Treated with Chemoradiotherapy Followed by Durvalumab
Tuller, M.
Buela, G.
Ferreira, Y.
Antivero, A.
Lupinacci, L.
Basbus, L.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S607 - S608
[27] Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer
Garassino, Marina C.
Paz-Ares, Luis
Hui, Rina
Faivre-Finn, Corinne
Spira, Alex
Planchard, David
Ozguroglu, Mustafa
Daniel, Davey
Vicente, David
Murakami, Shuji
Langer, Corey
Senan, Suresh
Spigel, David
Ryden, Anna
Zhang, Yiduo
O'Brien, Cathy
Dennis, Phillip A.
Antonia, Scott J.
FUTURE ONCOLOGY, 2021, 17 (10) : 1165 - 1184
[28] PD-L1 Expression in Patients with Non-small Cell Lung Cancer
Masago, Katsuhiro
Fujita, Shiro
Hata, Akito
Okuda, Chiyuki
Kaji, Reiko
Katakami, Nobuyuki
Hirata, Yukio
ANTICANCER RESEARCH, 2017, 37 (05) : 2269 - 2274
[29] PD-L1 heterogeneity in patients with non-small cell lung cancer
Wei, Zhigang
Fan, Linlin
Yang, Xia
Li, Jie
Zhan, Xuemei
Ye, Xin
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (05) : E268 - E274
[30] PD-L1 immunohistochemistry in patients with non-small cell lung cancer
Jotatsu, Takanobu
Oda, Keishi
Yatera, Kazuhiro
JOURNAL OF THORACIC DISEASE, 2018, 10 : S2127 - S2129

← 1 2 3 4 5 →